Thermo Fisher Scientific Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $18.27B (year ended Dec 31, 2016) to $44.56B (year ended Dec 31, 2025), a compound annual growth rate of 10.4%. The fastest growth was +26.1% in the year ended Dec 31, 2020; the weakest year was −4.6% (year ended Dec 31, 2023).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $44.56B | +3.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2026 |
| Dec 31, 2024 | $42.88B | +0.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2026 |
| Dec 31, 2023 | $42.86B | −4.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2026 |
| Dec 31, 2022 | $44.91B | +14.5% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 20, 2025 |
| Dec 31, 2021 | $39.21B | +21.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 22, 2024 |
| Dec 31, 2020 | $32.22B | +26.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 23, 2023 |
| Dec 31, 2019 | $25.54B | +4.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 24, 2022 |
| Dec 31, 2018 | $24.36B | +16.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2021 |
| Dec 31, 2017 | $20.92B | +14.5% | Revenues | 10-K filed Feb 28, 2018 |
| Dec 31, 2016 | $18.27B | +7.7% | Revenues | 10-K filed Feb 28, 2018 |
Thermo Fisher Scientific Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 26, 2026 | $12.14B | +9.1% | 10-Q filed Oct 30, 2026 |
| 3 months ended Jun 27, 2026 | $11.99B | +10.5% | 10-Q filed Jul 31, 2026 |
| 3 months ended Mar 28, 2026 | $11.01B | +6.2% | 10-Q filed May 1, 2026 |
| 3 months ended Sep 27, 2025 | $11.12B | +4.9% | 10-Q filed Oct 30, 2026 |
| 3 months ended Jun 28, 2025 | $10.86B | +3.0% | 10-Q filed Jul 31, 2026 |
| 3 months ended Mar 29, 2025 | $10.36B | +0.2% | 10-Q filed May 1, 2026 |
| 3 months ended Sep 28, 2024 | $10.60B | +0.2% | 10-Q filed Oct 31, 2025 |
| 3 months ended Jun 29, 2024 | $10.54B | −1.4% | 10-Q filed Aug 1, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 97745 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.